Is Biotricity, Inc. technically bullish or bearish?
2025-09-20 19:26:18As of 2 September 2025, the technical trend for Biotricity, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average. The KST is also bullish on a weekly basis, while the monthly indicators show a mildly bullish stance. However, the RSI shows no signal on both weekly and monthly time frames. The Bollinger Bands indicate a mildly bullish trend weekly but are sideways monthly. Overall, the Dow Theory shows no trend weekly and mildly bullish monthly. In terms of performance, Biotricity has a year-to-date return of 114.87%, significantly outperforming the S&P 500's 12.22% during the same period. However, over longer periods, the stock has underperformed, with a 3-year return of -90.97% compared to the S&P 500's 70.41%. The current stance is bullish, with moderate strength indicated by the weekly MACD and moving averages, despite some mixed signa...
Read MoreIs Biotricity, Inc. overvalued or undervalued?
2025-09-20 18:02:11As of 14 February 2020, the valuation grade for Biotricity, Inc. moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued, as evidenced by a Price to Book Value of -0.44 and an EV to EBITDA ratio of -8.26, both of which suggest significant financial distress. Additionally, the company's P/E ratio is not applicable due to it being loss-making, further complicating its valuation. In comparison to its peers, Biotricity's valuation metrics are concerning; for instance, CareCloud, Inc. has a P/E of 12.655, while Biotricity's is -3.7032, highlighting a stark contrast in financial health. Other risky peers like Intellinetics, Inc. and Zenvia, Inc. also show negative valuations, with EV to EBITDA ratios of -49.2573 and 4.5867, respectively. Notably, Biotricity's recent stock performance has been volatile, with a YTD return of 114.87% compared to the S&P...
Read More





